Here are four key notes:
1. Researchers analyzed randomized controlled trials comparing at least one week of H. pylori therapy with placebo or no treatment in preventing development of gastric cancer.
2. Six trials met all the researchers’ eligibility criteria and provided extractable data. Five trials were conducted in Asian populations.
3. In preventing development of subsequent gastric cancer, H. pylori eradication therapy was superior to placebo or no treatment.
4. The effect of H. pylori eradication on preventing death from gastric cancer compared with placebo or no treatment was uncertain due to wide confidence intervals.
More articles on GI/endoscopy:
GI physician compensation: 13 statistics
FDA clears 2 new HCV drugs
Chromoendoscopy vs. conventional colonoscopy: IBD surveillance
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
